Alterations in striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease

被引：0
|
作者：
Hallett, PJ
Dunah, AW
Crossman, AR
Brotchie, JM
Standaert, DG
机构：
来源：
MOVEMENT DISORDERS | 2004年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P531
引用
收藏
页码：S189 / S190
页数：2
相关论文
共 50 条
  • [41] mGlu5 Receptors in Parkinson's Disease and MPTP-Lesioned Monkeys: Behavior and Brain Molecular Correlates
    Morin, N.
    Ouattara, B.
    Gregoire, L.
    Morissette, M.
    Samadi, P.
    Gasparini, F.
    Rajput, A.
    Rajput, A. H.
    Gomez-Mancilla, B.
    Di Paolo, T.
    CURRENT NEUROPHARMACOLOGY, 2014, 12 : 44 - 44
  • [42] The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future
    Bjorklund, Anders
    Cenci, M. Angela
    RECENT ADVANCES IN PARKINSONS DISEASE: TRANSLATIONAL AND CLINICAL RESEARCH, 2010, 184 : 133 - 157
  • [43] Dopamine D2, but not D3, receptor activation is responsible for the antiparkinsonian actions of ropinirole in the MPTP-lesioned marmoset model of Parkinson's disease
    Silverdale, M
    Michael, HP
    Crossman, AR
    Millan, M
    Catherine, R
    Jonathan, BM
    MOVEMENT DISORDERS, 2002, 17 : S60 - S60
  • [44] The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease
    Visanji, Naomi P.
    de Bie, Rob M. A.
    Johnston, Tom H.
    McCreary, Andrew C.
    Brotchie, Jonathan M.
    Fox, Susan H.
    MOVEMENT DISORDERS, 2008, 23 (13) : 1922 - 1925
  • [45] Effect of Histamine H2 Receptor Antagonism on Levodopa-Induced Dyskinesia in the MPTP-Macaque Model of Parkinson's Disease
    Johnston, Tom H.
    van der Meij, Anne
    Brotchie, Jonathan M.
    Fox, Susan H.
    MOVEMENT DISORDERS, 2010, 25 (10) : 1379 - 1390
  • [46] Preclinical Development of AAV2-hGDNF Gene Delivery for Parkinson's Disease: Functional Recovery of MPTP-Lesioned Rhesus Monkeys
    Kells, Adrian
    Eberling, Jamie
    Hadaczek, Piotr
    Pivirotto, Philip
    Beyer, Janine
    Forsayeth, John
    Bankiewicz, Krystof
    MOLECULAR THERAPY, 2009, 17 : S190 - S190
  • [47] Prior treatment with PYM50028, an orally active neurotrophic factor modulator in development for Parkinson's disease, reduces L-Dopa induced dyskinesia in MPTP-lesioned macaques
    Johnston, T. H.
    Fox, S. H.
    Howson, P. A.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2011, 26 : S281 - S282
  • [48] The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
    Beaudry, Francis
    Huot, Philippe
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (10) : 1343 - 1358
  • [49] The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
    Francis Beaudry
    Philippe Huot
    Journal of Neural Transmission, 2020, 127 : 1343 - 1358
  • [50] Synergistic anti-dyskinetic effect of topiramate and amantadine in the MPTP-lesioned non-human primate model of Parkinson's disease
    Kobylecki, C.
    Crossman, A. R.
    Paula, R.
    MOVEMENT DISORDERS, 2010, 25 (07) : S402 - S402
12345